Tumor-draining lymph nodes of primary lung cancer patients: A potent source of tumor-specific killer cells and dendritic cells

Anticancer Research

Volumn 25, Issue 1 A, 2005, Pages 85-94

  Kimura, Hideki ^a   Dobrenkov, Konstantin ^a   Iida, Tomohiko ^a   Suzuki, Makoto ^a   Ando, Sohichiro ^a   Yamamoto, Naotaka ^a  

^a CHIBA CANCER CENTER   (Japan)

Author keywords

CTL; Dendritic cell; Immunotherapy; Lung cancer; Lymph node; Sentinel node

Indexed keywords

CD14 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CELL SURFACE MARKER; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CHROMIUM 51 RELEASE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KILLER CELL; LUNG CANCER; LYMPH NODE; LYMPHOCYTE; MONOCYTE; PERIPHERAL LYMPHOCYTE; PHAGOCYTE; PRIORITY JOURNAL; SENTINEL LYMPH NODE; TUMOR DRAINING LYMPH NODE; TUMOR GROWTH;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-2; KILLER CELLS; LUNG NEOPLASMS; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; T-LYMPHOCYTES;

EID: 16344394030     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Santin AD: Lymph node metastases: the importance of the microenvironment. Cancer 88: 175-9, 2000.
2. Evans EM, Man S, Evans AS and Borysiewicz LK: Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T lymphocytes. Cancer Res 57: 2943-50, 1997.
3. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC and Cerundolo V: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytotoxic T lymphocytes. J Exp Med 188: 1641-50, 1998.
4. Matsumura T, Sussman JJ, Krinock RA, Chang AE and Shu S: Characteristics and in vivo homing of long term T cell lines and clones derived from tumor-draining lymph nodes. Cancer Res 54: 2744-50, 1994.
5. Kimura H and Yamaguchi Y: Cytotoxic activity of various LAK cells against autologous lung cancer, K-562 and Daudi cells. Jap J Clin Oncol 19: 222-8, 1989.
6. Vuylsteke RJ, van Leeuwen PA, Meijer S, Wijnands PG, Statius Muller MG, Busch DH, Scheper RJ and de Gruijl TD: Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol 161: 19-26, 2002.
7. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJ, Adema GJ, Punt C and Figdor CG: Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63: 12-7, 2003.
8. Cochran AJ, Morton DL, Stern S, Lana AM, Essner R and Wen DR: Sentinel lymph nodes show profound down regulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 14: 604-8, 2001.
9. Ishigami S, Natsugoe S, Hokita S, Xiangming C, Aridome K, Iwashige H, Tokuda K, Nakajo A, Miyazono F and Aikou T: Intranodal antitumor immunocyte infiltration in node-negative gastric cancers. Clin Cancer Res 6: 2611-7, 2000.
10. Sasada T, Kimura M, Yoshida Y, Kanai M and Takabayashi A: CD4+CD25+regulatory T cells in patients with gastrointestinal malignancies. Cancer 98: 1089-99, 2003.
11. Tanaka H, Tanaka J, Kjaergaard J and Shu S: Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25: 207-17, 2002.
12. Biggs MW and Eiselein JE: Suppression of immune surveillance in melanoma. Med Hypotheses 56: 648-52, 2001.
13. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E and Chen L: Tumor-associated B7-H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800, 2002.
14. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen L and Zou W: Blockade of B7-H1 improves myeloid dendritic cell-mediated anti-tumor immunity. Nat Med 9: 562-7, 2003.
15. O'Neill HC, Jonas N, Wilson H and Ni K: Immunotherapeutic potential of dendritic cells generated in long-term stroma-dependent cultures. Cancer Biother Radiopharm 14: 263-76, 1999.
16. O'Neill HC, Ni K and Wilson H: Long-term stroma-dependent cultures are a consistent source of immunostimulatory dendritic cells. Immunol Cell Biol 77: 434-41, 1999.
17. Tanigawa K, Takeshita N, Eickhoff GA, Shimizu K and Chang AE: Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines. J Immunother 24: 493-501, 2002.
18. Gatza E and Okada CY: Tumor cell lysate-pulsed dendritic cells are more effective than TCR 1d protein vaccines for active immunotherapy of T cell lymphoma. J Immunol 770: 5227-35, 2003.
19. Santin AD, Bellone S, Ravaggi A, Roman JJ, Pecorelli S, Parham GP and Cannon MJ: Induction of tumor-specific CD8(+) cytotoxic T lymphocytes by tumor lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. Br J Cancer 86: 151-7, 2002.
20. Kass R, Agha J, Bellone S, Palmieri M, Cane S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S and Santin AD: In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. J Surg Res 112: 189-97, 2003.
21. Kimura H and Yamaguchi Y: Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. Lung Cancer 13: 31-44, 1995.
22. Kimura H and Yamaguchi Y: Adjuvant chemo-immunotherapy after curative resection of stage II and IIIA primary lung cancer. Lung Cancer 14: 301-14, 1996.
23. Kimura H and Yamaguchi Y: A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 80: 42-9, 1997.
24. Suzuki M, Kimura H, Iwai N and Fujisawa T: Intermittent adjuvant chemo- immunotherapy after resection of non-small cell lung cancer with multilevel mediastinal lymph node metastasis. Oncology Rep 7: 545-9, 2000.
25. Mulé JJ: Dendritic cells: at the clinical crossroads. J Clin Invest 105: 707-8, 2000.
26. Schmidt T, Ziske C, Marten A, Endres S, Tiemann K, Schmitz V, Gorschluter M, Schneider C, Sauerbruch T and Schmidt-Wolf IG: Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic tumor model. Cancer Res 63: 8962-7, 2003.
27. Lord EM and Frelinger JG: Tumor immunotherapy: cytokines and antigen presentation. Cancer Immunol Immunother 46: 75-81, 1998.